Comment: Immunotherapy plus chemotherapy in bladder cancer

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Comment: Keynote 522 trial

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer